GlowCap Reminder System in Patients With Early Stage Breast Cancer Receiving Adjuvant Endocrine Therapy
Terminated
- Conditions
- Breast Cancer
- Interventions
- Other: GlowCap device
- Registration Number
- NCT01239251
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Brief Summary
The purpose of this study is to test the ease of using a new device, called the GlowCap that reminds the patient to take their breast cancer hormone pill. The study will collect information about the experience with this device and what the patient thinks of its role in the daily pill taking routine.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- Female
- Target Recruitment
- 8
Inclusion Criteria
- Early stage breast cancer patients taking adjuvant endocrine therapy (ie, tamoxifen, anastrozole, letrozole, exemestane).
- Age ≥ 60 years
- Must have broadband internet access at home (to enable the base for the system to communicate to the Vitality server).
- Must have a landline or mobile phone
Read More
Exclusion Criteria
- Non-English speaking patients
Read More
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description breast cancer patients taking endocrine therapy GlowCap device Breast cancer patients, currently taking adjuvant endocrine therapy will be equipped with a GlowCap device for a period of 30 days. The GlowCap will become part of their medication taking routine.
- Primary Outcome Measures
Name Time Method Assess the usability of the GlowCap system by patients 2 years \>60 years of age with early stage breast cancer.
- Secondary Outcome Measures
Name Time Method Measure the acceptance and satisfaction of the GlowCap reminder system 2 years with respect to medication adherence in patients \>60 years with early stage breast cancer taking adjuvant endocrine therapy.
Trial Locations
- Locations (1)
Memorial Sloan Kettering Cancer Center 1275 York Avenue
🇺🇸New York, New York, United States